Management of advanced primary urethral carcinomas

Area of Science:

• Urology
• Oncology
• Genitourinary Cancer Research

Background:

• Primary urethral carcinoma (PUC) is a rare genitourinary malignancy, predominantly affecting men and African-Americans.
• Histology and site vary by gender; squamous cell carcinoma is most common, with adenocarcinomas seen in women.
• Common presentations include obstructive/irritative symptoms and hematuria.

Purpose of the Study:

• To review the epidemiology, clinical presentation, diagnostic methods, and treatment strategies for primary urethral carcinoma.
• To identify prognostic factors and discuss current therapeutic approaches for both early and advanced stages of PUC.
• To highlight the need for further multi-institutional studies due to the rarity of the disease.

Main Methods:

• Literature review and synthesis of existing data on primary urethral carcinoma.
• Analysis of diagnostic modalities including cystourethroscopy and MRI.
• Evaluation of treatment outcomes based on disease stage, location, and gender.

Main Results:

• Prognostic factors in men include disease location and stage; in women, tumor size is also significant.
• Early-stage PUC benefits from surgery and radiation therapy (RT).
• Advanced PUC requires multimodal treatment, including induction chemotherapy, surgery, RT, or chemoradiation, with potential for organ preservation.

Conclusions:

• Optimal treatment for advanced primary urethral carcinoma necessitates multimodal strategies, potentially involving chemoradiation, drawing parallels with HPV-related cancers.
• Prospective, multi-institutional studies are crucial to establish definitive treatment guidelines for this rare cancer.
• Understanding prognostic factors like stage, location, and tumor size is vital for tailoring treatment and improving survival in PUC.